+

WO2008113364A3 - Amino derivatives to prevent nephrotoxicity and cancer - Google Patents

Amino derivatives to prevent nephrotoxicity and cancer Download PDF

Info

Publication number
WO2008113364A3
WO2008113364A3 PCT/DK2008/050070 DK2008050070W WO2008113364A3 WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3 DK 2008050070 W DK2008050070 W DK 2008050070W WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cell
cancer
treatment
amino derivatives
Prior art date
Application number
PCT/DK2008/050070
Other languages
French (fr)
Other versions
WO2008113364A2 (en
Inventor
Soeren Valdgaard Boye
Jacob Thinggaard
Original Assignee
Recepticon Aps
Soeren Valdgaard Boye
Jacob Thinggaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepticon Aps, Soeren Valdgaard Boye, Jacob Thinggaard filed Critical Recepticon Aps
Priority to EP08715624A priority Critical patent/EP2139461A2/en
Publication of WO2008113364A2 publication Critical patent/WO2008113364A2/en
Publication of WO2008113364A3 publication Critical patent/WO2008113364A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In an embodiment, the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of blocking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds.
PCT/DK2008/050070 2007-03-20 2008-03-19 Amino derivatives to prevent nephrotoxicity and cancer WO2008113364A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08715624A EP2139461A2 (en) 2007-03-20 2008-03-19 Amino derivatives to prevent nephrotoxicity and cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700424 2007-03-20
DKPA200700424 2007-03-20
DKPA200700958 2007-06-29
DKPA200700958 2007-06-29

Publications (2)

Publication Number Publication Date
WO2008113364A2 WO2008113364A2 (en) 2008-09-25
WO2008113364A3 true WO2008113364A3 (en) 2009-04-16

Family

ID=39529323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050070 WO2008113364A2 (en) 2007-03-20 2008-03-19 Amino derivatives to prevent nephrotoxicity and cancer

Country Status (2)

Country Link
EP (1) EP2139461A2 (en)
WO (1) WO2008113364A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5777846B2 (en) 2005-06-15 2015-09-09 マサチューセッツ インスティテュート オブ テクノロジー Amine-containing lipids and uses thereof
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CN102421417B (en) 2009-05-05 2016-03-02 阿尔尼拉姆医药品有限公司 Lipid composition
LT3338765T (en) 2009-12-01 2019-06-25 Translate Bio, Inc. Steroid derivative for the delivery of mrna in human genetic diseases
CA2807661C (en) * 2010-08-11 2019-09-10 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
EP4458350A3 (en) 2011-06-08 2025-01-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
MX363734B (en) 2011-10-27 2019-03-29 Massachusetts Inst Technology Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres.
WO2013148230A1 (en) * 2012-03-28 2013-10-03 University Of Central Florida Research Foundation, Inc. Polyamine transport selective therapeutic agents with enhanced stability
EP2854829A1 (en) * 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
EP2970955B1 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. Methods for purification of messenger rna
SG11201507391VA (en) 2013-03-14 2015-10-29 Shire Human Genetic Therapies Cftr mrna compositions and related methods and uses
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
CA2928429C (en) 2013-10-28 2022-08-30 Drexel University Aminoalkyl phenyl derivatives useful in the treatment of adhd and other cognitive disorders
JP6571679B2 (en) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
JP6557722B2 (en) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Biodegradable lipids for delivery of nucleic acids
SG11201610670WA (en) 2014-06-24 2017-01-27 Shire Human Genetic Therapies Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
CA2986930C (en) 2015-06-24 2023-09-26 Duke University Chemical modulators of signaling pathways and therapeutic use
CA3054062A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
MA49138A (en) 2017-05-16 2020-03-25 Translate Bio Inc TREATMENT OF CYSTIC FIBROSIS BY ADMINISTRATION OF CODON-OPTIMIZED MRNA CODING FOR CFTR
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557A1 (en) 2018-11-21 2021-06-10 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07118148A (en) * 1993-10-26 1995-05-09 Tsumura & Co Liver cancer prevention agent
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
WO1998010757A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1999022744A1 (en) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Use of aliphatic polyamines for reducing oxalate
WO1999051213A2 (en) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
WO2003092668A1 (en) * 2002-05-02 2003-11-13 Johannes Wohlrab Use of agmatine for topical application
WO2004084876A2 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2004084799A2 (en) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO2005060569A2 (en) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Tame based chelators and uses thereof
WO2006037335A2 (en) * 2004-10-06 2006-04-13 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2006040579A1 (en) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Bioactive polymers
WO2006119713A2 (en) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Antineoplastic compounds and pharmaceutical compositions thereof
WO2008107471A2 (en) * 2007-03-07 2008-09-12 Dextech Medical Ab Modified hydroxypolymer conjugates with killing effect on tumor cells

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
JPH07118148A (en) * 1993-10-26 1995-05-09 Tsumura & Co Liver cancer prevention agent
WO1998010757A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO1999022744A1 (en) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Use of aliphatic polyamines for reducing oxalate
WO1999051213A2 (en) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
WO2003092668A1 (en) * 2002-05-02 2003-11-13 Johannes Wohlrab Use of agmatine for topical application
WO2004084876A2 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2004084799A2 (en) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
WO2005060569A2 (en) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Tame based chelators and uses thereof
WO2006037335A2 (en) * 2004-10-06 2006-04-13 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2006040579A1 (en) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Bioactive polymers
WO2006119713A2 (en) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Antineoplastic compounds and pharmaceutical compositions thereof
WO2008107471A2 (en) * 2007-03-07 2008-09-12 Dextech Medical Ab Modified hydroxypolymer conjugates with killing effect on tumor cells

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BASU, HIRAK S. ET AL: "Correlation between the effects of polyamine analogs on DNA conformation and cell growth", CANCER RESEARCH , 49(20), 5591-7 CODEN: CNREA8; ISSN: 0008-5472, 1989, XP007906534 *
BRANA, M. F. ET AL: "Chromophore-Modified Bis-Naphthalimides: Synthesis and Antitumor Activity of Bis-Dibenz[de,h]isoquinoline-1,3-diones", JOURNAL OF MEDICINAL CHEMISTRY , 40(4), 449-454 CODEN: JMCMAR; ISSN: 0022-2623, 1997, XP007906538 *
CAMPHAUSEN K ET AL: "Evaluation of chelating agents as anti-angiogenic therapy through copper chelation", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 19, 1 October 2004 (2004-10-01), pages 5133 - 5140, XP004558891, ISSN: 0968-0896 *
COVASSIN, LAURENCE ET AL: "Synthesis of spermidine and norspermidine dimers as high affinity polyamine transport inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 9(12), 1709-1714 CODEN: BMCLE8; ISSN: 0960-894X, 1999, XP002506782 *
COVASSIN, LAURENCE ET AL: "Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 13(19), 3267-3271 CODEN: BMCLE8; ISSN: 0960-894X, 2003, XP007906533 *
DIMMOCK J ET AL: "Mannich bases of phenolic azobenzenes possessing cytotoxic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 7-8, 1 July 1997 (1997-07-01), pages 583 - 594, XP004372794, ISSN: 0223-5234 *
EDWARDS M L ET AL: "POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY. POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 33, no. 5, 1 May 1990 (1990-05-01), pages 1369 - 1375, XP000604648, ISSN: 0022-2623 *
LEVINE, SEYMOUR ET AL: "Hypothalamic and medullary lesions caused by an aliphatic triamine unrelated to goldthioglucose", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY , 41(1), 54-66 CODEN: JNENAD; ISSN: 0022-3069, 1982, XP009109539 *
MUIR C P ET AL: "Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 96, no. 2, 1 March 2006 (2006-03-01), pages 169 - 176, XP019274993, ISSN: 1573-7217 *
NG, CHIU YUEN ET AL: "1,4-Bis[2,5,5-tris(carboxymethyl)-2,5-diazapentyl]benzene (PXED3A): synthesis, binuclear chelating tendencies, and iron(III) .mu.-oxo-bridge formation", INORGANIC CHEMISTRY , 22(5), 721-8 CODEN: INOCAJ; ISSN: 0020-1669, 1983, XP007906530 *
OGUCHI, HISAO ET AL: "Effect of lactose derivatives on metastatic potential of B16 melanoma cells", CANCER COMMUNICATIONS , 2(9), 311-16 CODEN: CNCMET; ISSN: 0955-3541, 1990, XP009109561 *
PALMER, BRIAN D. ET AL: "Synthesis, DNA binding interactions and biological activity of bis-platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines", ANTI-CANCER DRUG DESIGN , 7(5), 385-401 CODEN: ACDDEA; ISSN: 0266-9536, 1992, XP002939720 *
RUSTENBECK I ET AL: "Polyamine modulation of mitochondrial calcium transport. II. Inhibition of mitochondrial permeability transition by aliphatic polyamines but not by aminoglucosides.", BIOCHEMICAL PHARMACOLOGY 15 OCT 1998, vol. 56, no. 8, 15 October 1998 (1998-10-15), pages 987 - 995, XP007906535, ISSN: 0006-2952 *
RUSTENBECK, INGO ET AL: "Polyamine modulation of mitochondrial calcium transport, I. Stimulatory and inhibitory effects of aliphatic polyamines, aminoglycosides and other polyamine analogs on mitochondrial calcium uptake", BIOCHEMICAL PHARMACOLOGY , 56(8), 977-985 CODEN: BCPCA6; ISSN: 0006-2952, 1998, XP007906539 *
SHA, S.-H. ET AL: "Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant", HEARING RESEARCH , 142(1-2), 34-40 CODEN: HERED3; ISSN: 0378-5955, 2000, XP007906532 *
SHAH, NEHA ET AL: "Activation of Nuclear Factor .kappa.B by Polyamines in Breast Cancer Cells", BIOCHEMISTRY , 38(45), 14763-14774 CODEN: BICHAW; ISSN: 0006-2960, 1999, XP007906536 *
SIBERT, JOHN W. ET AL: "Lipophilic derivatives of cyclam as new inhibitors of tumor cell growth", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM) , (2), 154-155 CODEN: CHCOFS; ISSN: 1359-7345, 2002, XP007906537 *
TAKAO K ET AL: "Studies on inhibition of enzymatic arginyltransfer reaction", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, vol. 46, no. 7, 1 January 1998 (1998-01-01), pages 1169 - 1172, XP009109711, ISSN: 0009-2363 *
WILLIAMS P D ET AL: "Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 237, no. 3, 1 January 1986 (1986-01-01), pages 919 - 925, XP009109529, ISSN: 0022-3565 *
ZANG, ERLE ET AL: "Synthesis of hexamine ligands by using trityl as an N-blocking group", SYNTHETIC COMMUNICATIONS , 27(18), 3145-3150 CODEN: SYNCAV; ISSN: 0039-7911, 1997, XP009109581 *

Also Published As

Publication number Publication date
WO2008113364A2 (en) 2008-09-25
EP2139461A2 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2008113364A3 (en) Amino derivatives to prevent nephrotoxicity and cancer
WO2004084876A3 (en) Use of compounds for the prevention of drug-induced cell toxicity
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
NZ577916A (en) Cyclopamine analogs
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008012532A3 (en) : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MX2009012155A (en) A synergistic pharmaceutical combination for the treatment of cancer.
UA105390C2 (en) Normal;heading 1;heading 2;heading 3;CHEMICAL MODIFICATION MOTIFS FOR MIRNA INHIBITORS AND MIMETICS
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MY155695A (en) Quinoxalinedione derivatives
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
AU2007249926A8 (en) Monocyclic heteroaryl compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715624

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008715624

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载